Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Feb 5, 2024

31100_dirs_2024-02-05_93e9b334-4b4b-4ddb-aea0-697df296554f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2013-02-01

Reporting Person: PICKERING GRANT (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-01 Common Stock S 119 $71.934 Disposed 151167 Indirect
2024-02-01 Common Stock S 491 $73.255 Disposed 150676 Indirect
2024-02-01 Common Stock S 443 $74.366 Disposed 150233 Indirect
2024-02-01 Common Stock S 255 $75.473 Disposed 149978 Indirect
2024-02-01 Common Stock S 134 $71.931 Disposed 151152 Indirect
2024-02-01 Common Stock S 655 $73.341 Disposed 150497 Indirect
2024-02-01 Common Stock S 238 $74.562 Disposed 150259 Indirect
2024-02-01 Common Stock S 281 $75.486 Disposed 149978 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 375814 Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.995 to $73.37. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.01 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.21 to $75.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F7: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F8: Shares are held directly by a trust for the benefit of the Reporting Person's son.

F9: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.01 to $73.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F10: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.13 to $75.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F11: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.23 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.